Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

83%

5 of 6 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

N/A

4(80.0%)

Phase 2

1(20.0%)

5Total

N/A(4)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT01808560Not ApplicableCompleted

Treatment of Meibomian Gland Dysfunction Prior to Cataract Surgery

Role: lead

NCT02102464Not ApplicableCompleted

Treatment of Meibomian Gland Dysfunction and Dry Eye in Contact Lens Wearers

Role: lead

NCT00761917Completed

Diagnostic Evaluation of the Tear Film

Role: lead

NCT01521507Not ApplicableCompleted

Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye

Role: lead

NCT00832130Not ApplicableCompleted

Treatment of Meibomian Gland Dysfunction and Evaporative Dry Eye

Role: lead

NCT01202747Phase 2Completed

Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction

Role: lead

All 6 trials loaded